Erwin van Wijk is a researcher at Radboudumc’s national centre of expertise for hereditary hearing loss: Hearing and Genes. He aims to make a significant contribution towards finding a treatment for the debilitating Usher syndrome. He doesn’t want to count his chickens before they hatch, but the results are better than he had dared to hope for. With a slightly different approach, the method he is using could potentially also prove valuable for other hereditary conditions, such as DFNA9.
Van Wijk speaks with great enthusiasm about the medical research projects he is involved in. He is conducting research into two hereditary conditions: Usher syndrome and DFNA9. The term ‘genetic patch’ often comes up in this context. “That has indeed been the central theme running through my scientific career in recent years,” he says. “In both studies, we have developed a genetic patch, but they do differ from one another.”
Deafness and blindness
Usher syndrome is an inherited condition that affects both hearing and vision and can ultimately lead to complete deafness and blindness. It is estimated that between 600 and 1,000 people in the Netherlands are affected by this condition. Van Wijk has been conducting research into it since 2004. “Usher syndrome involves a small number of genes containing errors. These errors disrupt the production of functional proteins. The genetic patch ensures that the part of a gene containing the error – known as an exon – is masked and not recognised. The exon in question, containing the genetic error, is no longer included in the code that is translated into protein. The result is that a slightly truncated protein is produced, and the key question is whether that protein is functional enough to allow the eye and ear to function relatively normally. That is the main focus of the research.”
The efficacy of the first gene therapy for Usher syndrome type 2a is currently being tested in patients. This therapy has been specifically developed for exon 13 of the USH2A gene. This is where the mutation lies in some patients with Usher syndrome type 2a. “So this research won’t be able to help all Usher patients. But if we can develop an effective treatment for this group, we’re still talking about around 16,000 people worldwide.”
Van Wijk deliberately refers to ‘preserving’ eye and ear function. His research into Usher syndrome – which is unique in the world – was initially aimed at halting the progression of the disease, not at bringing about an improvement. But the results of the second phase of the clinical trial, which were announced last year, were better than he had dared to hope for. “There even appeared to be a slight improvement in vision, even among people whose disease was already at an advanced stage. That was a wonderful finding that we hadn’t expected.”
The third phase of the clinical trial began recently, involving a larger group of patients. The results will not be known for another three years. “Hopefully, all the data will hold up and the drug will then be brought to market.”
Timely intervention at DFNA9
Meanwhile, Van Wijk and his colleagues have also been working for around four years on a genetic treatment for the rare hereditary condition DFNA9. This condition causes people to suddenly experience rapid hearing loss from around the age of 35, as well as severe balance problems. “It is a condition caused by a defect in the DNA that occurs almost exclusively in the Netherlands and Belgium. The interesting thing about the disease is that it is possible to intervene before people experience the first symptoms and thus potentially prevent the problems from manifesting.”
Research into DFNA9 is at a much earlier stage than that into Usher syndrome. The so-called proof of concept has been completed, a patent has been granted, and two major research grants have recently been secured to further develop the promising findings.
The genetic patch is different, partly because DFNA9 is dominantly inherited rather than recessively inherited, as is Usher syndrome, explains Van Wijk. “In DFNA9, there is a fault in the COCH gene. Once translated, this defect leads to the clumping of the cochlin protein, which is deposited in the inner ear. With the genetic patch, we are trying to specifically break down the mutated copy of the gene so that no proteins are produced from it.” It is therefore a different mechanism to the one Van Wijk uses for Usher syndrome, but the knowledge gained is certainly useful. “We have reused what we learnt about developing an effective genetic patch, even though the patches work in a different way.”
Other diseases
The knowledge now gained may now be able to be applied to other diseases and conditions. "We thought the size of the DFNA9 patient population was unique, because hereditary hearing impairment is so heterogeneous. But now we have stumbled upon another form of dominantly inherited hearing impairment: DFNA21. This involved finding a specific genetic error in the RIPOR2 gene that is estimated to occur thousands of times in north-western Europe. All due to the same genetic mutation. This is quite extraordinary. The underlying disease mechanism is roughly the same as in DFNA9, so we might be able to repeat some of that trick. That could certainly also apply to other disease states with a similar underlying disease mechanism that might not even involve deafness or blindness. This approach has great potential."
Still many opportunities
Consequently, Van Wijk's research group is busy. "With the research grants we have received, we can put a lot of energy into DFNA9 research in the coming years. In Usher syndrome, we are going to see if we can expand it. We are now looking at whether our method with the genetic patch can also be used in other types of Usher syndrome, such as for type 2c, among others. Together with US researchers, we are conducting research into type 1f. In this way, we are contributing to the wonderful mission of the Usher Syndrome Foundation to make the disease treatable before 2025. We are also looking at other methods, such as removing exons using the CRISPR-Cas system and developing scaled-down versions of Usher genes: minigenes. Yes, we still have more than enough to do."
Lights on green
Through a confluence of circumstances, Van Wijk once rolled into Usher research. "It came my way fairly by chance. I find it very fascinating and beautiful, especially because you are involved in the research from start to finish. From discovering the gene to, hopefully, developing a therapy with which we can give patients a positive outlook. Our own data and the results of the trials look positive. We can never look into the future and anything can still go wrong, but for now, all the lights are on green. That gives a lot of energy."


